bsm-33278M-Cy3 [Conjugated Primary Antibody]
AKT1 Monoclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: AKT1

Immunogen Range: 420-479/479


Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 207

Swiss Prot: P31749

Source: KLH conjugated synthetic peptide derived from human AKT1

Purification: Purified by Protein G.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Mutations in this gene have been associated with the Proteus syndrome. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2011]

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • X Zhou et al. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action. BMC Psychiatry. 2020 Mar 6;20(1):106.Read more>>
  • Shuang Huet al. MicroRNA-708 prevents ethanol-induced hepatic lipid accumulation and inflammatory reaction via direct targeting ZEB1. Life Sci. 2020 Oct 1;258:118147.Read more>>
  • Le Tian. et al. Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model. Int Immunopharmacol. 2021 May;94:107441Read more>>
  • Yilei Li. et al. Vitellogenin 2 promotes muscle development and stimulates the browning of white fat. Aging-Us. 2021 Oct 15; 13(19): 22985C23003Read more>>
  • Chen Luyao. et al. Epicatechin gallate prevents the de novo synthesis of fatty acid and the migration of prostate cancer cells. Acta Bioch Bioph Sin. 2021 OcRead more>>
  • Chen, Yao. et al. The potential effects and mechanisms of_hispidulin in the treatment of diabetic retinopathy based on_network pharmacology. BMC Complementary Medicine and Therapies. 2022 Dec;22(1):1-12Read more>>
  • Yao Lei. et al. Phytochemical natural killer cells reprogram tumor microenvironment for potent immunotherapy of solid tumors. BIOMATERIALS. 2022 Jun;:121635Read more>>
  • Wang, Weili. et al. Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. NAT COMMUN. 2022 Aug;13(1):1-17Read more>>
  • Xiao-Jiao Chen. et al. Extracts of Knoxia roxburghii (Spreng.) M. A. Rau Induce Apoptosis in Human MCF-7 Breast Cancer Cells via Mitochondrial Pathways. MOLECULES. 2022 Jan;27(19):6435Read more>>
  • Rui Sun. et al. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy. CELL SIGNAL. 2023 Jan;101:110497Read more>>
  • Yang, Chong. et al. TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs. CELL DEATH DIS. 2023 Jan;14(1):1-13Read more>>
  • Ying Gao. et al. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228?cells. CHEM-BIOL INTERACT. 2023 Jul;379:110516Read more>>
  • Li Li. et al. Regulation of TREM2 on BV2 inflammation through PI3K/AKT/mTOR pathway. BIOTECHNOL GENET ENG. 2023 Apr 26Read more>>
  • Li Gu. et al. Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex. PHARMACOL RES. 2023 Jun;192:106789Read more>>
  • Qianfeng Liu. et al. Perfluoroalkyl substances promote breast cancer progression via ER and GPER mediated PI3K/Akt and MAPK/Erk signaling pathways. ECOTOX ENVIRON SAFE. 2023 Jun;258:11498Read more>>
  • Junfeng Wang. et al. Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT-mTOR pathway. MOL CARCINOGEN. 2023 MayRead more>>
  • Zhao Jiamin. et al. Sea buckthorn oil regulates primary myoblasts proliferation and differentiation in vitro. IN VITRO CELL DEV-AN. 2023 Dec;:1-12Read more>>
  • Yong Wei. et al. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer. AGING-US. 2024 Mar 31; 16(6): 5387C5411Read more>>
  • Yuan Yan. et al. Study on the mechanism of heterogeneous tumor-associated macrophages in three subtypes of breast cancer through the integration of single-cell RNA sequencing and in vitro experiments. MOL BIOL REP. 2024 Dec;51(1):1-16Read more>>
  • Jingzhan Huang. et al. Guanine-Rich RNA Sequence Binding Factor 1 Deficiency Promotes Colorectal Cancer Progression by Regulating PI3K/AKT Signaling Pathway. CANCER MANAG RES. 2024 11Read more>>
  • Yunhao Ma. et al. Synthesis and Biological Activity of 2-Chloro-8-methoxy-5-methyl-5H-indolo [2,3-b] Quinoline for the Treatment of Colorectal Cancer by Modulating PI3K/AKT/mTOR Pathways. ACS OMEGA. 2024;XXXX(XXX):XXX-XXXRead more>>
VALIDATION IMAGES